One of the very few fellowship-trained reconstructive and neuro-urologists in South Florida, Dr. Gousse is the Director of Bladder Health Program of South Florida, South Broward Hospital Districts. He is the Fellowship Director of Female Pelvic Medicine and Reconstructive Urology at the Memorial Hospital Miramar. He is a former tenured Professor of Urology at the University of Miami Miller School of Medicine, Department of Urology, Vice-Chairman of the University of Miami Hospital and Clinics Urology service, where he was also the Urology Residency Program Director and Fellowship Director for Female Urology, Urodynamics, and Reconstructive Surgery for more than ten years. Dr. Gousse received his medical degree with highest honors from the Yale University School of Medicine. He completed his residency at the Baylor College of Medicine in Houston Texas and a postdoctoral fellowship in Urodynamics, female urology and pelvic floor reconstruction at the University of California, Los Angeles. Certified by the American Board of Urology and Female Pelvic Medicine and Reconstructive Surgery.

An international leader in voiding dysfunction, he pioneered the optimal dosage of neurotoxins (Botox ) to manage bladder dysfunction. His investigator-initiated research projects on Botox chemodernervation in human subjects led to the first FDA urologic indication of Botox in the United States, the Neurogenic bladder trial. Dr. Gousse also participated and co-authored in clinical trials which led to the FDA approval of the first Beta-3 drug to treat overactive bladder, Merebegron ( marketed as Myrbetriq ) . He also collaborated on extramural NIH grants with Dr Vinata Lokeshwar to investigate urinary markers for interstitial cystitis. Dr. Gousse has authored or co-authored more than 90 peer-reviewed scientific publications and numerous textbook chapters, journal articles and abstracts.